הלוואות ואשראי לטווח ארוך של החברה: DiaMedica Pharma (DMAC)

DiaMedica Therapeutics focuses on developing kidney and brain therapies through physician partnerships and patent acquisitions. Financial quote visualization on GURU.Markets confirms that long-term debt stands at 0.00. Meanwhile, a lack of profitability leaves the company dependent on external financing, and its market resilience relies exclusively on the trial results of the innovative DM199 protein.

This metric reflects the total volume of obligations with a maturity of more than one year, determining the long-term financial stability of the issuer. Analyzing the value of DiaMedica Therapeutics (DMAC) long-term loans and borrowings allows an investor to assess the risk of credit pressure and the probability of a liquidity deficit. An increase in this metric signals an accumulation of imbalances, which is critical amid high borrowing costs. For DiaMedica Therapeutics (DMAC), this is a key indicator for controlling the cash burn rate during the clinical trials of the DM199 drug.